Twist Bioscience Corporation
A maker of synthetic DNA, Twist Bioscience writes custom genes and gene fragments on tiny silicon chips, shrinking the synthesis process dramatically. Its tools help researchers and drug developers discover and optimize antibodies, while its NGS products—target enrichment probes, library prep kits, and synthetic controls—are used in diagnostic tests for cancer, rare disease, and infectious disease. The company serves over 3,800 customers worldwide.
Granted 907.9K · Sold 354.1K
Granted 86.2K · Sold 2.1K
Granted 463.4K · Sold 327.6K
Granted 221.7K · Sold 121.8K
Granted 179.4K · Sold 70.3K
Granted 15.4K
Granted 33.9K
Granted 153.0K · Sold 91.6K
Granted 32.5K · Sold 31.3K
Granted 53.0K · Sold 35.5K
Granted 5.1K
Granted 5.8K
Granted 27.4K · Sold 21.2K
Granted 15.4K
Granted 10.3K
Granted 15.4K · Sold 4.5K
Granted 19.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Leproust Emily M.Chief Executive Officer, Director · 86 transactions | +212.3% | 770.7K | 907.9K | — | 354.1K |
| Banyai WilliamSee Remark · 16 transactions | +28.6% | 345.2Kas of May 2024 | 86.2K | — | 2.1K |
| Finn Patrick JohnPresident and COO · 75 transactions | +128.8% | 210.8K | 463.4K | — | 327.6K |
| Green PaulaSVP of Human Resources · 68 transactions | +447.1% | 117.9K | 221.7K | — | 121.8K |
| Laponis AdamChief Financial Officer · 31 transactions | — | 108.6K | 179.4K | — | 70.3K |
| Crandell KeithDirector · 3 transactions | +17.4% | 103.6K | 15.4K | — | — |
| Thorburn James MChief Financial Officer · 9 transactions | +44.2% | 86.3Kas of Jan 2024 | 33.9K | — | — |
| Cho DennisSee Remarks · 76 transactions | +156.5% | 74.1K | 153.0K | — | 91.6K |
| Chess RobertDirector · 15 transactions | — | 63.6K | 32.5K | — | 31.3K |
| Werner Robert F.Chief Accounting Officer · 51 transactions | — | 44.6K | 53.0K | — | 35.5K |
| Chan NelsonDirector · 1 transaction | — | 33.3K | 5.1K | — | — |
| Mai XiaoyingDirector · 1 transaction | +23% | 31.1Kas of Feb 2024 | 5.8K | — | — |
| Johannessen JanDirector · 7 transactions | +156.1% | 29.8K | 27.4K | — | 21.2K |
| Ragusa Robert PDirector · 3 transactions | +113.1% | 29.0K | 15.4K | — | — |
| Chan Nelson CDirector · 2 transactions | +57.6% | 28.2Kas of Feb 2025 | 10.3K | — | — |
| Starovasnik Melissa A.Director · 7 transactions | +96% | 22.2K | 15.4K | — | 4.5K |
| Blake KatrynDirector · 2 transactions | — | 19.4K | 19.4K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: -1.06M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.